Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: TRN018
MIFTS: 56

Transitional Cell Carcinoma

Categories: Cancer diseases, Nephrological diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Transitional Cell Carcinoma

About this section

MalaCards integrated aliases for Transitional Cell Carcinoma:

Name: Transitional Cell Carcinoma 12 74 52 15 17
Carcinoma, Transitional Cell 43 71
Transitional Cell Neoplasm 12 71
Transitional Cell Carcinoma of Bladder 71
Carcinoma Transitional Cell 54
Urothelial Cell Carcinoma 12
Transitional Cell Tumor 12
Transitional Carcinoma 12

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2671
MeSH 43 D002295
NCIt 49 C2930 C6783
SNOMED-CT 67 118287003 27090000
UMLS 71 C0007138 C0279680 C0334265
Sources

Summaries for Transitional Cell Carcinoma

About this section
Disease Ontology : 12 A carcinoma that derives from transitional epithelial cells.

MalaCards based summary : Transitional Cell Carcinoma, also known as carcinoma, transitional cell, is related to sarcomatoid transitional cell carcinoma and renal pelvis transitional cell carcinoma. An important gene associated with Transitional Cell Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Vitamin D3 and Vitamin D have been mentioned in the context of this disorder. Affiliated tissues include prostate, kidney and lymph node, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Transitional cell carcinoma, also called urothelial carcinoma, is a type of cancer that typically occurs... more...

Sources

Related Diseases for Transitional Cell Carcinoma

About this section

Diseases related to Transitional Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 776)
# Related Disease Score Top Affiliating Genes
1 sarcomatoid transitional cell carcinoma 35.2 TP53 CDH1
2 renal pelvis transitional cell carcinoma 34.7 UPK3A KRT7
3 urethra transitional cell carcinoma 34.6 UPK3A TP53
4 bladder papillary transitional cell neoplasm 33.9 UPK3A TP53 KRT20 FGFR3 BRINP1
5 papillary transitional carcinoma 33.6 UPK3A TP53 KRT7 KRT20 BRINP1
6 small cell carcinoma of the bladder 33.6 KRT7 KRT20
7 fallopian tube carcinoma 33.4 TP53 PTEN ERBB2
8 bladder urothelial carcinoma 33.1 UPK3A UPK2 TP53 PTEN MKI67 KRT7
9 prostate cancer 32.6 TP53 PTEN MKI67 HRAS ERBB3 ERBB2
10 urinary tract papillary transitional cell benign neoplasm 32.3 UPK3A TP53 KRT20 FGFR3 BRINP1
11 in situ carcinoma 32.0 TP53 PTEN HRAS ERBB2 EGFR CDKN2A
12 squamous cell papilloma 31.8 TP53 HRAS CDKN2A
13 bladder cancer 31.8 UPK3A UPK2 UPK1A TP53 PTEN MKI67
14 hydronephrosis 31.4 UPK3A UPK2 UPK1B KRT7
15 cystitis 31.4 UPK3A UPK1A TP53 KRT7 KRT20 CDH1
16 ovarian brenner tumor 31.4 UPK3A KRT7 KRT20
17 papillary carcinoma 31.2 KRT7 KRT20 ERBB2 CDH1 BRAF
18 papilloma 31.2 TP53 PTEN KRT7 KRT20 FGFR3 EGFR
19 inverted papilloma 31.2 TP53 MKI67 KRT7 KRT20 EGFR CDKN2A
20 renal cell carcinoma, nonpapillary 31.2 TP53 PTEN MKI67 KRT7 KRT20 HRAS
21 appendix adenocarcinoma 31.1 KRT7 KRT20 HRAS
22 small cell carcinoma 31.1 TP53 PTEN KRT7 KRT20 EGFR CDKN2A
23 exanthem 31.1 HRAS ERBB2 EGFR
24 spindle cell carcinoma 31.1 KRT7 HRAS CDH1
25 horseshoe kidney 31.1 KRT7 KRT20 EGFR
26 mammary paget's disease 31.1 KRT7 KRT20 ERBB2 EGFR
27 ureteral benign neoplasm 30.9 UPK3A KRT7
28 mucinous adenocarcinoma 30.9 TP53 KRT7 KRT20 ERBB2 EGFR CDKN2A
29 thyroid carcinoma 30.9 PTEN HRAS CDH1 BRAF
30 adenocarcinoma 30.9 TP53 PTEN KRT7 KRT20 HRAS FGFR3
31 clear cell adenocarcinoma 30.8 TP53 KRT7 KRT20
32 nevus, epidermal 30.8 PTEN HRAS FGFR3
33 interstitial cystitis 30.8 UPK3A UPK1A CDH1
34 serous cystadenocarcinoma 30.8 TP53 PTEN KRT7 HRAS ERBB2 CDKN2A
35 vesicoureteral reflux 1 30.8 UPK3A UPK2 UPK1B UPK1A
36 villous adenoma 30.8 TP53 KRT20 HRAS BRAF
37 glandular cystitis 30.8 UPK3A TP53 KRT7 KRT20
38 adenoma 30.8 TP53 MKI67 KRT7 KRT20 CDKN2A CDH1
39 cystitis cystica 30.8 UPK2 KRT7 KRT20
40 actinic keratosis 30.8 TP53 KRT20 HRAS CDKN2A
41 paget disease, extramammary 30.8 KRT7 KRT20 ERBB2
42 cystadenocarcinoma 30.7 TP53 KRT7 HRAS ERBB2 BRAF
43 lynch syndrome 30.7 TP53 PTEN HRAS ERBB2 EGFR CDKN2A
44 squamous cell carcinoma 30.7 TP53 PTEN MKI67 KRT7 HRAS FGFR3
45 collecting duct carcinoma 30.7 KRT7 KRT20 ERBB2 CDKN2A
46 keratosis 30.7 TP53 HRAS FGFR3 EGFR CDKN2A
47 urethral diverticulum 30.7 UPK3A KRT7
48 signet ring cell adenocarcinoma 30.7 TP53 KRT7 KRT20 HRAS ERBB2 CDH1
49 papillary adenocarcinoma 30.7 TP53 KRT7 HRAS ERBB2 CDH1
50 suppression of tumorigenicity 12 30.7 TP53 PTEN KRT7 HRAS ERBB2 EGFR

Graphical network of the top 20 diseases related to Transitional Cell Carcinoma:



Diseases related to Transitional Cell Carcinoma
Sources

Symptoms & Phenotypes for Transitional Cell Carcinoma

About this section

GenomeRNAi Phenotypes related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.41 EGFR HRAS BRAF
2 Decreased viability GR00055-A-2 10.41 EGFR HRAS BRAF
3 Decreased viability GR00106-A-0 10.41 ERBB3
4 Decreased viability GR00221-A-1 10.41 CDH1 CDKN2A EGFR FGFR3 HRAS
5 Decreased viability GR00221-A-2 10.41 FGFR3 HRAS ERBB3 EPHB2
6 Decreased viability GR00221-A-3 10.41 CDKN2A FGFR3 HRAS ERBB2 EPHB2
7 Decreased viability GR00221-A-4 10.41 CDKN2A EGFR BRAF ERBB2 ERBB3
8 Decreased viability GR00249-S 10.41 FGFR3 BRAF
9 Decreased viability GR00301-A 10.41 CDH1 BRAF ERBB3
10 Decreased viability GR00342-S-1 10.41 EPHB2
11 Decreased viability GR00381-A-1 10.41 BRAF
12 Decreased viability GR00386-A-1 10.41 EPHB2
13 Decreased viability GR00402-S-2 10.41 CDH1 EPHB2
14 Decreased cell migration GR00055-A-1 9.55 EPHB2 FGFR3
15 Decreased cell migration GR00055-A-3 9.55 BRAF EGFR HRAS
16 Reduced mammosphere formation GR00396-S 9.23 BRAF BRINP1 CDH1 EGFR ERBB3 HRAS

MGI Mouse Phenotypes related to Transitional Cell Carcinoma:

45 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.38 BRAF BRINP1 CDH1 CDKN2A EGFR EPHB2
2 growth/size/body region MP:0005378 10.36 BRAF BRINP1 CDH1 CDKN2A EGFR EPHB2
3 homeostasis/metabolism MP:0005376 10.35 BRAF BRINP1 CDH1 CDKN2A EGFR ERBB2
4 digestive/alimentary MP:0005381 10.29 BRAF CDH1 CDKN2A EGFR EPHB2 ERBB2
5 mortality/aging MP:0010768 10.28 BRAF BRINP1 CDH1 CDKN2A EGFR EPHB2
6 endocrine/exocrine gland MP:0005379 10.22 BRAF CDH1 CDKN2A EGFR EPHB2 ERBB2
7 integument MP:0010771 10.2 BRAF CDH1 CDKN2A EGFR ERBB2 ERBB3
8 embryo MP:0005380 10.19 BRAF CDH1 CDKN2A EGFR ERBB2 ERBB3
9 nervous system MP:0003631 10.11 BRAF BRINP1 CDKN2A EGFR EPHB2 ERBB2
10 craniofacial MP:0005382 10.1 BRAF EGFR EPHB2 ERBB2 FGFR3 HRAS
11 neoplasm MP:0002006 10.1 BRAF CDH1 CDKN2A EGFR ERBB2 ERBB3
12 normal MP:0002873 10 BRAF CDH1 EGFR ERBB2 ERBB3 FGFR3
13 hearing/vestibular/ear MP:0005377 9.97 BRAF EGFR EPHB2 FGFR3 TP53 UBIAD1
14 no phenotypic analysis MP:0003012 9.92 BRINP1 CDH1 CDKN2A EGFR FGFR3 HRAS
15 pigmentation MP:0001186 9.7 BRAF CDKN2A EGFR ERBB3 PTEN TP53
16 renal/urinary system MP:0005367 9.65 BRAF EGFR EPHB2 FGFR3 HRAS KRT7
17 respiratory system MP:0005388 9.28 BRAF CDKN2A EGFR ERBB2 ERBB3 FGFR3
Sources

Drugs & Therapeutics for Transitional Cell Carcinoma

About this section

Drugs for Transitional Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 281)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
2
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
3 Calciferol Phase 4
4
Methylcobalamin Approved, Investigational Phase 3 13422-55-4
5
Hydroxocobalamin Approved Phase 3 13422-51-0 15589840 11953898
6
Lapatinib Approved, Investigational Phase 2, Phase 3 231277-92-2, 388082-78-8 208908 9941095
7
Panitumumab Approved, Investigational Phase 3 339177-26-3 50070211
8
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
9
Amphotericin B Approved, Investigational Phase 2, Phase 3 1397-89-3 5280965 14956
10
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
11
Aminolevulinic acid Approved Phase 3 106-60-5 137
12
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
13
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
14
Melphalan Approved Phase 3 148-82-3 460612 4053
15
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
16
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
17
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
18
Durvalumab Approved, Investigational Phase 3 1428935-60-7
19
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60700
20
Lenvatinib Approved, Investigational Phase 3 417716-92-8
21
Tranexamic Acid Approved Phase 2, Phase 3 1197-18-8 5526
22
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
23
Olaparib Approved Phase 3 763113-22-0 23725625
24
Gemcitabine Approved Phase 3 95058-81-4 60750
25
leucovorin Approved Phase 3 58-05-9 6006 143
26
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
27
Ethanol Approved Phase 3 64-17-5 702
28
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
29
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
30
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
31
Vinblastine Approved Phase 3 865-21-4 241903 13342
32
Valrubicin Approved Phase 2, Phase 3 56124-62-0 41744
33
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
34
Cephalexin Approved, Investigational, Vet_approved Phase 3 15686-71-2 27447
35
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
36
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
37
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
38
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
39
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
40
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
41
Cobalamin Experimental Phase 3 13408-78-1 6857388
42 Tocotrienol Investigational Phase 3 6829-55-6
43
Levulinic acid Experimental Phase 3 123-76-2 11579
44
Fenretinide Investigational Phase 3 65646-68-6
45
Tremelimumab Investigational Phase 3 745013-59-6
46
Cediranib Investigational Phase 3 288383-20-0 9933475
47 Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
48 Vitamin B 12 Phase 3
49 Vitamin B12 Phase 3
50 BB 1101 Phase 3

Interventional clinical trials:

(show top 50) (show all 566)
# Name Status NCT ID Phase Drugs
1 Pilot Study of the Biological Effects of Vitamin D in Patients With Resectable Urinary Tract Urothelial Carcinoma Recruiting NCT04197089 Phase 4 Vitamin D
2 A Randomised Phase II/III Study of Cabazitaxel Versus Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium Unknown status NCT01830231 Phase 2, Phase 3 Cabazitaxel;Vinflunine
3 Adjuvant vs. Progression-Triggered Treatment With Gemcitabine After Radical Cystectomy for Locally Advanced Transitional Cell Carcinoma of the Bladder in Patients Not Suitable for Cisplatin-Based Chemotherapy - A Phase 3 Study Unknown status NCT00146276 Phase 3 gemcitabine
4 Intensified Methotrexate, Vinblastine, Doxorubicin and Cisplatin +/-Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma in Patients Without Harvey Nor Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations. Phase II Study Unknown status NCT02818725 Phase 3 Chemotherapy;panitumumab
5 A Prospective Randomized Phase III Trial of Maintenance Pemetrexed Versus Observation in Patients With Recurrent or Metastatic Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Without Disease Progression Unknown status NCT03193788 Phase 3 pemetrexed;Folic Acid;Vitamin B12 Injection;Dexamethasone
6 Phase III Randomized Study of a Single Adjunctive Instillation of Intravesical AD 32 (N-Trifluoroacetyladriamycin-14-valerate) Versus No Adjunctive Therapy Immediately Following Transurethral Resection in Patients With Multiple Superficial (Ta/T1) Bladder Tumors Unknown status NCT00003725 Phase 3 valrubicin
7 Phase III Study Of Adjuvant Cisplatin-Gemcitabine Vs. Observation After Radical Cystectomy In High-Risk Bladder Cancer Unknown status NCT00054626 Phase 3 cisplatin;gemcitabine hydrochloride
8 Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [TREATMENT] Unknown status NCT00553345 Phase 3 selenium;vitamin E
9 Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) Unknown status NCT00553124 Phase 3 selenium;vitamin E
10 A Phase II/III, Randomised, Two-Arm, Comparison of Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With HER1 and/or HER2 Overexpressing Locally Advanced or Metastatic Bladder Cancer [LaMB] Unknown status NCT00949455 Phase 2, Phase 3 lapatinib ditosylate
11 A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy Completed NCT00389155 Phase 2, Phase 3 Vinflunine;Gemcitabine
12 Prospective, Randomized Phase III Trial of I.V. Vinflunine Plus Best Supportive Care as Second Line Therapy Versus Best Supportive Care After a Platinum-containing Regimen, in Patients With Advanced Transitional Cell Carcinoma of Urothelial Tract Completed NCT00315237 Phase 3 vinflunine and best supportive care
13 Cabazitaxel in Platinum Pre-treated Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma Who Developed Disease Progression Within 12 Months of Platinum Based Chemotherapy. Completed NCT01668459 Phase 2, Phase 3 Cabazitaxel
14 Phase III Trial of Methotrexate, Vinblastine, Doxorubicin and Cisplatin vs Carboplatin and Paclitaxel in Advanced Carcinoma of the Urothelium Completed NCT00003376 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine
15 A Randomised Trial of Radical Chemo/Radiotherapy vs Radiotherapy Alone in the Definitive Management of Localised Muscle Invasive TCC of the Urinary Bladder Completed NCT00330499 Phase 3 Cisplatin
16 Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Cisplatin/Gemcitabine in Patients With Metastatic or Locally Advanced Urothelial Cancer Without Prior Systemic Therapy Completed NCT00022191 Phase 3 cisplatin;gemcitabine hydrochloride;paclitaxel
17 Randomized Phase III Trial Comparing Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients With pT3-pT4, and/or N+M0 Transitional Cell Carcinoma (TCC) of the Bladder Completed NCT00028756 Phase 3 doxorubicin hydrochloride;gemcitabine hydrochloride;vinblastine sulfate;methotrexate;cisplatin
18 Randomized Phase II/III Study Assessing Gemcitabine/Carboplatin And Methotrexate/Carboplatin/Vinblastine In Previously Untreated Patients With Advanced Urothelial Cancer Ineligible For Cisplatin Based Chemotherapy Completed NCT00014274 Phase 2, Phase 3 carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate
19 A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine Completed NCT02101931 Phase 3 Amino levulinic Acid
20 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
21 Phase III Randomized, Double-Blind Study of DFMO vs. Placebo in Low Grade Superficial Bladder Cancer Completed NCT00003814 Phase 3 eflornithine
22 Megadose Vitamins as Chemoprevention of Transitional Cell Carcinoma of the Bladder Completed NCT00003623 Phase 3
23 Phase III Randomized Chemoprevention Study of Selenium on the Recurrence of Non-invasive Bladder Cancer Completed NCT00729287 Phase 3
24 Phase III Study Comparing Sequential Chemotherapy (AG-ITP) To Cisplatin And Gemcitabine As Adjuvant Treatment After Cystectomy For Transitional Cell Carcinoma Of The Bladder Completed NCT00014534 Phase 3 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride
25 Randomised Trial of Selective Bladder Preservation Against Radical Excision (Cystectomy) in Muscle Invasive T2/T3 Transitional Cell Carcinoma of the Bladder - Feasibility Study Completed NCT00867347 Phase 3
26 A Phase III Randomized Trial of Either M-VAC or Paclitaxel + Carboplatin as Postoperative Adjuvant Therapy in Patients With Muscle-Invasive Transitional Cell Carcinoma of the Bladder at High-Risk for Relapse Completed NCT00003701 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine sulfate
27 A Multicenter Randomized Trial of Radical Radiotherapy With Carbogen in the Radical Treatment of Locally Advanced Bladder Cancer Completed NCT00033436 Phase 3 carbogen
28 A RANDOMIZED TRIAL OF RADICAL RADIOTHERAPY IN pT1G3 NXM0 BLADDER CANCER Completed NCT00002490 Phase 3 mitomycin C
29 Open-label, Multi-center Study of the Efficacy and Safety of MCC in the Treatment of Patients With Non-muscle Invasive (Superficial) Bladder Cancer at High Risk of Progression and Who Are Refractory to BCG Completed NCT00406068 Phase 2, Phase 3 Mycobacterial cell wall-DNA complex
30 Phase IIb/III Chemoprevention Trial of Celecoxib to Prevent Recurrence of Superficial Bladder Cancer Completed NCT00006124 Phase 2, Phase 3 celecoxib;placebo
31 Randomized Chemoprevention Trial With 4-HPR (Fenretinide) in Superficial Bladder Cancer Completed NCT00004154 Phase 3 Fenretinide
32 2X2 Factorial Randomized Phase III Study Comparing Standard Versus Reduced Volume Radiotherapy With and Without Synchronous Chemotherapy in Muscle Invasive Bladder Cancer Completed NCT00024349 Phase 3 fluorouracil;mitomycin C
33 Comparative Study of Intravesical BCG Standard Dose Long-Term Maintenance Versus BCG 1/3 Dose Long-Term Maintenance Versus BCG Standard Dose Short-Term Maintenance Versus BCG 1/3 Dose Short-Term Maintenance in Intermediate and High Risk Ta, T1 Papillary Carcinoma of the Urinary Bladder Completed NCT00002990 Phase 3
34 Sequential Bacillus Calmette-Guérin and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin Alone for High Risk Superficial Bladder Cancer: a Prospective Randomised Study Completed NCT01442519 Phase 3 electromotive mitomycin
35 A Phase III Blinded Study of Immediate Post TURBT Instillation of Gemcitabine Versus Saline in Patients With Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer Completed NCT00445601 Phase 3 gemcitabine hydrochloride
36 Phase III Trial of IV Vinflunine Versus an Alkylating Agent in Patients With Metastatic Breast Cancer Previously Treated With or Resistant to an Anthracycline, a Taxane, an Antimetabolite, and a Vinca-alkaloid (Study L00070 IN 308 B0) Completed NCT01091168 Phase 3 vinflunine;Alkylating agent of physician choice registered in cancer
37 A Phase 3, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of Either Cisplatin or Carboplatin +Gemcitabine + Tislelizumab Compared With Either Cisplatin or Carboplatin + Gemcitabine + Placebo as First-line Treatment for Patients With Locally Advanced or Metastatic Urothelial Carcinoma Recruiting NCT03967977 Phase 3 Tislelizumab;Placebo;Cisplatin;Gemcitabine Hydrochloride;Carboplatin
38 A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011) Recruiting NCT03898180 Phase 3 Lenvatinib;Placebo for lenvatinib
39 Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302) Recruiting NCT04197986 Phase 3 Infigratinib;Placebo
40 S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer Recruiting NCT03091660 Phase 3
41 Four Cycles of Cisplatin-Based Chemotherapy in Metastatic Urothelial Carcinoma Compared to Six Cycles: Randomized Phase III Trial - FOCUS Study - Recruiting NCT03296306 Phase 3 Treatment duration of cisplatin based chemotherapy
42 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Recruiting NCT00719303 Phase 3
43 Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG 1806) Recruiting NCT03775265 Phase 3 Atezolizumab;Cisplatin;Fluorouracil;Gemcitabine;Mitomycin
44 Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (Ambassador) Versus Observation Recruiting NCT03244384 Phase 3
45 A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) Recruiting NCT02502266 Phase 2, Phase 3 Cediranib;Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan;Topotecan Hydrochloride
46 A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer. Recruiting NCT03682068 Phase 3 Durvalumab;Tremelimumab;Cisplatin + Gemcitabine;Carboplatin + Gemcitabine
47 Tranexamic Acid During Cystectomy Trial (TACT) Recruiting NCT01869413 Phase 2, Phase 3 Tranexamic Acid;Placebo
48 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy Active, not recruiting NCT02426125 Phase 3 Ramucirumab;Docetaxel;Placebo
49 A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer Active, not recruiting NCT01993979 Phase 3 Chemotherapy
50 A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of MitoGelâ„¢ on Ablation of Upper Urinary Tract Urothelial Carcinoma Active, not recruiting NCT02793128 Phase 3 MitoGelâ„¢ instillations

Search NIH Clinical Center for Transitional Cell Carcinoma

Cochrane evidence based reviews: carcinoma, transitional cell

Sources

Genetic Tests for Transitional Cell Carcinoma

About this section
Sources

Anatomical Context for Transitional Cell Carcinoma

About this section

MalaCards organs/tissues related to Transitional Cell Carcinoma:

40
Prostate, Kidney, Lymph Node, Testes, Lung, Ovary, Bone
Sources

Publications for Transitional Cell Carcinoma

About this section

Articles related to Transitional Cell Carcinoma:

(show top 50) (show all 8596)
# Title Authors PMID Year
1
Sarcomatoid carcinoma of the urinary bladder: a case report with immunohistochemical and molecular genetic analysis. 61 54
19521796 2010
2
Potential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladder. 61 54
20428812 2010
3
Isoenzyme profile of glutathione transferases in transitional cell carcinoma of upper urinary tract. 61 54
20403581 2010
4
Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. 61 54
19888985 2010
5
p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. 54 61
20068172 2010
6
[Expressions of survivin and the splice variants survivin-2B and survivin-DeltaEx3 in bladder cancer and their clinical significance]. 54 61
19895744 2009
7
Selection of optimal antisense accessible sites of uroplakin II mRNA for bladder urothelium. 54 61
19513619 2009
8
Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17. 54 61
19443884 2009
9
A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. 54 61
19115207 2009
10
[Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder]. 54 61
19615282 2009
11
Sulforaphane down-regulates COX-2 expression by activating p38 and inhibiting NF-kappaB-DNA-binding activity in human bladder T24 cells. 54 61
19287971 2009
12
Soluble form of carbonic anhydrase IX (CAIX) in transitional cell carcinoma of urinary tract. 61 54
19473055 2009
13
Differential expression of survivin and its splice variants, survivin-DeltaEx3 and survivin-2B, in bladder cancer. 54 61
19186007 2009
14
Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: a long-term study. 61 54
18367096 2008
15
Systemic therapy for unresectable and metastatic transitional cell carcinoma of the urothelium: first-line and beyond. 54 61
18685414 2008
16
Identification of survivin, an inhibitor of apoptosis, in canine urinary bladder transitional cell carcinoma. 54 61
19178674 2008
17
p63 expression in ovarian tumours: immunopositivity in metastatic transitional cell carcinoma of the ovary. 61 54
18518899 2008
18
RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking. 54 61
18676844 2008
19
DNA polymorphisms in exon 1 and promoter of the CDH1 gene and relevant risk of transitional cell carcinoma of the urinary bladder. 61 54
18384629 2008
20
Insights from a whole cystectomy specimen--association of primary small cell carcinoma of the bladder with transitional cell carcinoma in situ. 54 61
18547617 2008
21
Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to Cisplatin. 61 54
18538698 2008
22
The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladder. 54 61
18430124 2008
23
Differential accumulation of hypericin in spheroids composed of T-24 transitional cell carcinoma cells expressing different levels of E-cadherin. 61 54
18355860 2008
24
SNPs of GSTM1, T1, P1, epoxide hydrolase and DNA repair enzyme XRCC1 and risk of urinary transitional cell carcinoma in southwestern Taiwan. 54 61
18199464 2008
25
Possible role of cyclooxygenase-2 in schistosomal and non-schistosomal-associated bladder cancer. 61 54
18449376 2008
26
Survivin: a promising biomarker for detection and prognosis of bladder cancer. 61 54
17962949 2008
27
Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents. 54 61
17603559 2008
28
Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder. 61 54
18645275 2008
29
Downregulation of survivin is associated with reductions in TNF receptors' mRNA and protein and alterations in nuclear factor kappa B signaling in urothelial cancer cells. 61 54
18058462 2007
30
Expression of CD44s and CD44v6 in transitional cell carcinomas of the urinary bladder: comparison with tumour grade, proliferative activity and p53 immunoreactivity of tumour cells. 61 54
18092951 2007
31
Expression of cyclooxygenase-2, P-glycoprotein and multi-drug resistance-associated protein in canine transitional cell carcinoma. 54 61
17316722 2007
32
Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. 61 54
17826525 2007
33
Bacillus Calmette-Guérin induces p21 expression in human transitional carcinoma cell lines via an immediate early, p53 independent pathway. 61 54
17483019 2007
34
Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. 54 61
17311305 2007
35
Expression of p63 in thymomas and normal thymus. 54 61
17276940 2007
36
Cyclooxygenase-2 in transitional cell carcinoma--a legitimate target? 54 61
17296349 2007
37
Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. 61 54
17296438 2007
38
Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. 61 54
17222615 2007
39
Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. 54 61
17155984 2007
40
Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder. 54 61
17987577 2007
41
P53 overexpression in bladder urothelial neoplasms: new aspect of World Health Organization/International Society of Urological Pathology classification. 61 54
18270948 2007
42
EZH2 polycomb transcriptional repressor expression correlates with methylation of the APAF-1 gene in superficial transitional cell carcinoma of the bladder. 54 61
17541304 2007
43
Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder. 54 61
16473461 2007
44
Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. 54 61
16949911 2006
45
Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer. 61 54
17133271 2006
46
Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment. 54 61
16984978 2006
47
Overexpression of PAX5 in oral carcinogenesis. 61 54
17016584 2006
48
The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder. 54 61
17024120 2006
49
The role of glutathione transferases M1 and T1 in individual susceptibility to bladder cancer in a Tunisian population. 54 61
17381051 2006
50
Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder. 61 54
16642478 2006
Sources

Variations for Transitional Cell Carcinoma

About this section

Copy number variations for Transitional Cell Carcinoma from CNVD:

7 (show top 50) (show all 92)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 26136 1 197500000 205300000 Amplification LRRN2 Urothelial cell carcinoma
2 26141 1 197500000 205300000 Amplification MDM4 Urothelial cell carcinoma
3 26154 1 197500000 205300000 Loss Urothelial cell carcinoma
4 42679 10 3800000 6700000 Amplification PFKFB3 Urothelial cell carcinoma
5 49670 11 110000000 115400000 Loss ANKK1 Urothelial cell carcinoma
6 49671 11 110000000 115400000 Loss DRD2 Urothelial cell carcinoma
7 49672 11 110000000 115400000 Loss NCAM1 Urothelial cell carcinoma
8 49673 11 110000000 115400000 Loss TTC12 Urothelial cell carcinoma
9 52333 11 16100000 21600000 Loss PLEKHA7 Urothelial cell carcinoma
10 58688 11 69200000 70700000 Amplification CCND1 Urothelial cell carcinoma
11 58689 11 69200000 70700000 Amplification FGF19 Urothelial cell carcinoma
12 58690 11 69200000 70700000 Amplification FGF3 Urothelial cell carcinoma
13 58692 11 69200000 70700000 Amplification FGF4 Urothelial cell carcinoma
14 58694 11 69200000 70700000 Amplification ORAOV1 Urothelial cell carcinoma
15 58695 11 69200000 70700000 Amplification TPCN2 Urothelial cell carcinoma
16 58889 11 70700000 74900000 Amplification Urothelial cell carcinoma
17 58890 11 70700000 74900000 Amplification C11orf76 Urothelial cell carcinoma
18 58891 11 70700000 74900000 Amplification SHANK2 Urothelial cell carcinoma
19 64483 12 128700000 132349534 Loss FZD10 Urothelial cell carcinoma
20 69470 12 55200000 56300000 Amplification ARHGAP9 Urothelial cell carcinoma
21 69471 12 55200000 56300000 Amplification DCTN2 Urothelial cell carcinoma
22 69472 12 55200000 56300000 Amplification GLI1 Urothelial cell carcinoma
23 69473 12 55200000 56300000 Amplification INHBC Urothelial cell carcinoma
24 69474 12 55200000 56300000 Amplification KIF5A Urothelial cell carcinoma
25 69475 12 55200000 61400000 Amplification CDK4 Urothelial cell carcinoma
26 69476 12 55200000 61400000 Amplification METTL1 Urothelial cell carcinoma
27 69477 12 55200000 61400000 Amplification TSFM Urothelial cell carcinoma
28 69795 12 56300000 61400000 Amplification FAM19A2 Urothelial cell carcinoma
29 69796 12 56300000 61400000 Amplification SLC16A7 Urothelial cell carcinoma
30 70900 12 66000000 69800000 Amplification CNOT2 Urothelial cell carcinoma
31 70901 12 66000000 69800000 Amplification CPM Urothelial cell carcinoma
32 70902 12 66000000 69800000 Amplification IFNG Urothelial cell carcinoma
33 70903 12 66000000 69800000 Amplification IL22 Urothelial cell carcinoma
34 70904 12 66000000 69800000 Amplification IL26 Urothelial cell carcinoma
35 70910 12 66000000 69800000 Amplification MDM2 Urothelial cell carcinoma
36 70911 12 66000000 69800000 Amplification TM4SF3 Urothelial cell carcinoma
37 71411 12 69800000 74100000 Amplification LGR5 Urothelial cell carcinoma
38 71412 12 69800000 74100000 Amplification THAP2 Urothelial cell carcinoma
39 71413 12 69800000 74100000 Amplification TMEM19 Urothelial cell carcinoma
40 71414 12 69800000 74100000 Amplification TPH2 Urothelial cell carcinoma
41 71668 12 74100000 78700000 Amplification NAV3 Urothelial cell carcinoma
42 72907 12 87500000 91200000 Amplification KITLG Urothelial cell carcinoma
43 73109 12 91200000 94800000 Amplification PLXNC1 Urothelial cell carcinoma
44 79797 13 77800000 86500000 Loss Urothelial cell carcinoma
45 94764 15 70400000 73100000 Loss SDFR1 Urothelial cell carcinoma
46 109762 17 28800000 35600000 Amplification ERBB2 Urothelial cell carcinoma
47 109763 17 28800000 35600000 Amplification TCAP Urothelial cell carcinoma
48 123109 18 66900000 71300000 Loss Urothelial cell carcinoma
49 123110 18 66900000 71300000 Loss SDCCAG33 Urothelial cell carcinoma
50 123111 18 66900000 71300000 Loss ZADH2 Urothelial cell carcinoma
Sources

Expression for Transitional Cell Carcinoma

About this section
Search GEO for disease gene expression data for Transitional Cell Carcinoma.
Sources

Pathways for Transitional Cell Carcinoma

About this section

Pathways related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.87 TP53 PTEN HRAS FGFR3 ERBB3 ERBB2
2
GPCR Pathway 63
Show member pathways
 13.74 TP53 HRAS FGFR3 ERBB3 ERBB2 EPHB2
3
TGF-Beta Pathway 63
Show member pathways
 13.58 TP53 HRAS FGFR3 ERBB3 ERBB2 EPHB2
4
Developmental Biology 65
Show member pathways
 13.54 KRT7 KRT20 HRAS FGFR3 ERBB3 ERBB2
5
Class I MHC mediated antigen processing and presentation 65
Show member pathways
 13.49 TP53 PTEN HRAS FGFR3 ERBB3 ERBB2
6
Akt Signaling 63
Show member pathways
 13.45 TP53 PTEN HRAS FGFR3 ERBB3 ERBB2
7
Cytokine Signaling in Immune system 65
Show member pathways
 13.39 TP53 HRAS FGFR3 ERBB3 ERBB2 EGFR
8
CREB Pathway 63
Show member pathways
 13.35 PTEN HRAS FGFR3 ERBB3 ERBB2 EPHB2
9
Nanog in Mammalian ESC Pluripotency 63
Show member pathways
 13.32 HRAS FGFR3 ERBB3 ERBB2 EPHB2 EGFR
10
IL-2 Pathway 63
Show member pathways
 13.25 TP53 PTEN HRAS ERBB3 ERBB2 EGFR
11
GAB1 signalosome 65
Show member pathways
 13.14 TP53 PTEN FGFR3 ERBB3 ERBB2 EGFR
12
Phospholipase-C Pathway 63
Show member pathways
 13.1 TP53 PTEN HRAS FGFR3 EGFR BRAF
13
PI3K-Akt signaling pathway 36
Show member pathways
 13.04 TP53 PTEN HRAS FGFR3 ERBB3 ERBB2
14
Actin Nucleation by ARP-WASP Complex 63
Show member pathways
 12.99 FGFR3 ERBB3 ERBB2 EPHB2 EGFR CDH1
15
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 12.94 PTEN HRAS ERBB3 ERBB2 EGFR BRAF
16
NFAT and Cardiac Hypertrophy 63
Show member pathways
 12.93 PTEN HRAS FGFR3 ERBB3 ERBB2 EGFR
17
Endometrial cancer 36
Show member pathways
 12.89 TP53 PTEN HRAS ERBB2 EGFR CDKN2A
18
Pathways in cancer 36
12.81 TP53 PTEN HRAS FGFR3 ERBB2 EGFR
19
MAPK signaling pathway 36 1
12.8 TP53 HRAS FGFR3 ERBB3 ERBB2 EGFR
20
Ras signaling pathway 36
Show member pathways
 12.76 HRAS FGFR3 EGFR CDH1 BRAF
21
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.76 TP53 PTEN HRAS FGFR3 ERBB3 ERBB2
22
Gastric cancer 36
Show member pathways
 12.76 TP53 PTEN HRAS ERBB2 EGFR CDKN2A
23
Development HGF signaling pathway 22
Show member pathways
 12.74 TP53 PTEN HRAS ERBB3 ERBB2 CDH1
24
ErbB signaling pathway 36 1
Show member pathways
 12.61 TP53 PTEN HRAS FGFR3 ERBB3 ERBB2
25
VEGF Signaling 66
Show member pathways
 12.57 TP53 PTEN HRAS FGFR3 EGFR CDH1
26
Apoptosis Pathway 70
Show member pathways
 12.51 TP53 HRAS FGFR3 ERBB3 ERBB2 EGFR
27
MicroRNAs in cancer 36
12.46 TP53 PTEN HRAS FGFR3 ERBB3 ERBB2
28
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.41 HRAS FGFR3 ERBB3 ERBB2 EPHB2 EGFR
29
Translation Non-genomic (rapid) action of Androgen Receptor 22
Show member pathways
 12.38 TP53 PTEN HRAS ERBB2 EGFR
30
Human T-cell leukemia virus 1 infection 36
12.37 TP53 PTEN HRAS CDKN2A
31
Development Ligand-independent activation of ESR1 and ESR2 22
Show member pathways
 12.35 HRAS ERBB3 ERBB2 EGFR
32
Development EGFR signaling pathway 22
Show member pathways
 12.35 HRAS ERBB3 ERBB2 EGFR CDH1 BRAF
33
Signaling by ERBB2 65
Show member pathways
 12.34 HRAS ERBB3 ERBB2 EGFR
34
Proteoglycans in cancer 36
12.34 TP53 HRAS ERBB3 ERBB2 EGFR BRAF
35
G-protein signaling Ras family GTPases in kinase cascades (scheme) 22
Show member pathways
 12.33 TP53 HRAS EGFR BRAF
36
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.33 TP53 PTEN HRAS FGFR3 ERBB3 ERBB2
37
EGF/EGFR Signaling Pathway 1
12.26 PTEN HRAS ERBB2 EGFR BRAF
38
Colorectal Cancer Metastasis 63
12.22 TP53 EGFR CDH1 BRAF
39
Integrated Breast Cancer Pathway 1
12.22 TP53 PTEN EGFR CDH1 BRAF
40
Glioma 36
Show member pathways
 12.21 TP53 PTEN HRAS ERBB3 ERBB2 EGFR
41
Cellular senescence (KEGG) 36
12.2 TP53 PTEN HRAS CDKN2A
42
Tyrosine Kinases / Adaptors 4
12.2 FGFR3 ERBB3 ERBB2 EPHB2 EGFR
43
MAPK Signaling: Mitogens 64
Show member pathways
 12.19 TP53 PTEN HRAS FGFR3 ERBB3 ERBB2
44
Development EGFR signaling via small GTPases 22
Show member pathways
 12.18 PTEN HRAS ERBB2 EGFR
45
FoxO signaling pathway 36
Show member pathways
 12.13 PTEN HRAS EGFR BRAF
46
Signaling by PTK6 65
Show member pathways
 12.11 HRAS ERBB3 ERBB2 EGFR
47
MAPK Pathway 70
Show member pathways
 12.1 TP53 ERBB3 ERBB2 EGFR BRAF
48
DNA Damage Response (only ATM dependent) 1
12.04 TP53 PTEN